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Abstract: Bacteriophage (phage), viruses that infect bacteria only, have become promising 
vectors for targeted systemic delivery of genes to cancer, although, with poor efficiency. 
We previously designed an improved phage vector by incorporating cis genetic elements of 
adeno-associated virus (AAV). This novel AAV/phage hybrid (AAVP) specifically 
targeted systemic delivery of therapeutic genes into tumors. To advance the AAVP vector, 
we recently introduced the stress-inducible Grp78 tumor specific promoter and found that 
this dual tumor-targeted AAVP provides persistent gene expression, over time, in cancer 
cells compared to silenced gene expression from the CMV promoter in the parental AAVP. 
Herein, we investigated the effect of histone deacetylation and DNA methylation on 
AAVP-mediated gene expression in cancer cells and explored the effect of cell confluence 
state on AAVP gene expression efficacy. Using a combination of AAVP expressing the 
GFP reporter gene, flow cytometry, inhibitors of histone deacetylation, and DNA 
methylation, we have demonstrated that histone deacetylation and DNA methylation are 
associated with silencing of gene expression from the CMV promoter in the parental 
AAVP. Importantly, inhibitors of histone deacetylases boost gene expression in cancer 
cells from the Grp78 promoter in the dual tumor-targeted AAVP. However, cell 
confluence had no effect on AAVP-guided gene expression. Our findings prove that 
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combination of histone deacetylase inhibitor drugs with the Grp78 promoter is an effective 
approach to improve AAVP-mediated gene expression in cancer cells and should be 
considered for AAVP-based clinical cancer gene therapy.  
Keywords: bacteriophage; phage-targeted gene transfer; cancer gene therapy; AAV/phage; 
Grp78; histone acetylation/deacetylation; DNA methylation 
 
1. Introduction 
Targeting therapeutic genes efficiently and specifically to tumors following systemic administration 
would present a major advance in cancer gene therapy. Animal viruses provide superior gene delivery 
vectors; however, they have had limited success in targeted systemic cancer gene therapy because of 
uptake by the liver and reticulo-endothelial system, broad tropism for normal tissues, and neutralizing 
antibodies [1]. Alternatively bacteriophage (phage), bacterial viruses, have attracted attention as safe 
vectors for targeted systemic gene delivery. Bacteriophage infect bacteria only and have no intrinsic 
tropism for mammalian or plant cells. However, if a mammalian ligand is displayed on the phage 
surface (targeted phage), the ligand can bind to its specific receptor on eukaryotic cells resulting in 
entry and internalization of the bacteriophage into the cells, eventually leading to the delivery of a 
eukaryotic transgene cassette inserted within the phage genome [2]. Despite some attractive features, 
bacteriophage viruses are still considered poor vectors. Unlike eukaryotic viruses, they have no 
intrinsic strategies for delivering genes to eukaryotic cells; however, we have previously reported that 
phage gene transfer efficacy can be improved [3–5]. We designed an improved phage vector, which 
incorporated a mammalian transgene cassette flanked by inverted terminal repeats (ITRs) from  
adeno-associated virus (AAV2) into the bacteriophage genome [3,6–8]. In this vector, named 
AAV/phage or AAVP, the targeted M13-derived phage served as a carrier to deliver the AAV2 
transgene cassette. Tumor targeting was achieved by displaying the RGD4C (CDCRGDCFC) ligand, 
on the phage capsid, to target overexpressed alpha v integrin receptors in tumors [3,9,10]. This phage 
vector showed improved gene transfer efficiency, which was associated with better fate of the vector 
genome through maintenance of the entire mammalian transgene cassette, better persistence of 
extrachromosomal vector DNA, and formation of concatamers of the AAV transgene cassette, or a 
combination of these non-mutually exclusive mechanisms [3,7]. Transgene expression by RGD4C/AAVP 
was driven by a cytomegalovirus (CMV) promoter, largely utilized in many gene therapy vectors to 
drive strong and constitutive expression of transgenes. However, this promoter is not specific and 
undergoes silencing by mammalian host cells [11–13]. Thus, to further improve AAVP at the genome 
level, we introduced a eukaryotic tumor specific promoter of the glucose regulated protein 78 (Grp78) 
to drive gene expression [14]. The Grp78 gene is selectively induced in tumors, but its activity is not 
detectable in major normal tissues [15]. We therefore generated a dual tumor-targeted RGD4C/AAVP-
Grp78 vector containing the RGD4C tumor homing ligand and Grp78 promoter [14]. In our  
previously published work, we reported that the double-targeted RGD4C/AAVP-Grp78 provides 
persistent transgene expression over RGD4C/AAVP-CMV carrying the CMV promoter [14]. Our 
recent work reporting silencing of the CMV promoter in both U87 and 9L cancer cells is consistent 
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with other studies [12,13,16]. Herein, we aimed to gain further insight into gene expression silencing 
from the RGD4C/AAVP-CMV phage vector, its persistence from RGD4C/AAVP-Grp78 and 
subsequently improved AAVP-mediated gene expression in cancer cells.  
2. Results and Discussion 
We monitored gene expression by AAVP in the human U87 and rat 9L glioblastoma cells over an 
extended time course by generating stably transduced cells with vectors carrying puro
R
 gene that 
confers puromycin resistance. A marked decrease in gene expression from the RGD4C/AAVP-CMV 
phage vector was observed over time in U87 and 9L cells; in contrast, no silencing of Grp78-regulated 
gene expression was detected following cell transduction with the double-targeted RGD4C/AAVP-
Grp78 phage (Figure 1).  
Figure 1. Persistence of gene expression from RGD4C/AAVP-Grp78 and silencing of 
RGD4C/AAVP-CMV-mediated gene delivery in cancer cells. U87 and 9L glioblastoma 
cells were stably transduced with RGD4C/AAVP-CMV-GFP or RGD4C/AAVP-Grp78-
GFP vectors. Then GFP positive cells were monitored by flow cytometry over a period of 
39 to 75 days post-transduction of U87 cells, and 39 to 97 days post-transduction of 9L 
cells. This experiment was repeated three times with similar results, shown are data of one 
experiment. Statistical analyses were performed by using GraphPad Prism software 
(version 5.0). Error bars represent standard error of the mean (s.e.m). p-values were 
generated by ANOVA and denoted as follows: * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
Although the exact mechanisms of viral promoter silencing have remained mainly unknown, 
several studies have demonstrated the association of DNA methylation and histone deacetylation with 
inactivation of the CMV promoter [11,13,16,17]. Generally, both DNA methylation and histone 
acetylation statuses play major roles in the regulation of gene expression by providing transcription 
factors’ accessibility to gene promoters. The precise balance of acetylated and deacetylated states of 
histones is an important feature of gene regulation and the imbalance is found in many human cancers, 
often resulting from alterations in histone acetyltransferase (HATs) and histone deacetylase (HDACs) 
enzyme activities. Here, we quantified AAVP-mediated gene expression in the presence of HDAC 
inhibitors by using vectors expressing the green fluorescent protein (GFP), RGD4C/AAVP-CMV-GFP 
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and RGD4C/AAVP-Grp78-GFP, and carrying the puro
R
 to generate stable gene expression by stably 
transduced cells. Flow cytometry was used and both percentage of GFP positive cells and mean 
fluorescent intensity (MFI) were calculated by normalizing the results to parental non-transduced cells. 
As an initial experiment, we evaluated GFP expression in the human U87 cancer cells transduced  
with RGD4C/AAVP-CMV-GFP or RGD4C/AAVP-Grp78-GFP upon treatment with increasing 
concentrations of trichostatin-A (TSA), a pan-HDAC inhibitor. TSA is the first characterized organic 
HDAC inhibitor [18] widely utilized to study the reactivation of silenced viral constructs. In 
RGD4C/AAVP-CMV-GFP-transduced U87 cells, treatment with 0.5 µM and 1 µM TSA resulted in a 
significant increase of both percentage of GFP positive cells by 1.4- and 1.8-fold, and MFI by 2.7- and 
3.0-fold, respectively (Figure 2A). These findings are consistent with previous reports demonstrating 
reactivation of the CMV promoter by TSA in U87 cells and other cell lines [12,19]. Interestingly, GFP 
expression in U87 cells stably transduced by RGD4C/AAVP-Grp78-GFP increased at the level of 
MFI only, upon TSA treatment, with no effect on GFP positive cells (Figure 2B). Next, we 
investigated additional HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA), which is 
structurally similar to TSA, as well as nicotinamide and valporic acid (VPA). SAHA treatment with 
0.5 µM and 1 µM yielded results comparable to TSA and resulted in a dose dependent reactivation of 
gene expression in U87 cells transduced with RGD4C/AAVP-CMV-GFP, enhancing the percentage of 
GFP positive cells by 1.6- and 2.2-fold, as well as MFI by 1.8- and 2.8-fold, respectively (Figure 2A). 
Interestingly, in RGD4C/AAVP-Grp78-GFP-transduced cells and similar to TSA treatment, only the 
MFI was increased upon SAHA treatment while the percentage of GFP positive cells remained intact 
(Figure 2B). Finally, treatment with either nicotinamide or VPA had no effect on GFP expression of 
U87 cells transduced with either RGD4C/AAVP-CMV-GFP (Figure 2A) or RGD4C/AAVP-Grp78-
GFP (Figure 2B). These results show that TSA and SAHA, both Zn
2+
 binding inhibitors of HDACs 
class I and II, restore GFP expression from RGD4C/AAVP-CMV in U87 cells; whereas, nicotinamide, 
a class III HDAC inhibitor, and VPA, an inhibitor of class I HDACs, had no effect on gene expression 
from the RGD4C/AAVP-CMV-GFP phage vector. Based on these observations we can postulate the 
involvement of HDAC class II in gene expression silencing from RGD4C/AAVP-CMV-GFP in U87 
cells. Interestingly, induction of RGD4C/AAVP-Grp78-guided gene expression by TSA and SAHA 
treatment was also reproduced in the 9L cells transduced with RGD4C/AAVP-Grp78-GFP, and 
consistently with U87 cells, only MFI was increased with no effect on GFP positive cells (Figure 2C). 
Again, nicotinamide and VPA inhibitors had no impact (Figure 2C). In contrast, TSA, SAHA, 
nicotinamide, and VPA treatment of 9L cells transduced with RGD4C/AAVP-CMV-GFP had no 
significant effect on GFP expression (data not shown). Consequently, we investigated an additional 
mechanism regulating the CMV promoter silencing, the promoter methylation status, to determine 
whether gene expression from the RGD4C/AAVP-CMV phage in 9L cells can be rescued by DNA 
methylation inhibitors. Thus, treatment with various concentrations of the DNA methylation inhibitor 
5-Azacytidine (5-Aza) resulted in a dose dependent increase of GFP expression in 9L cells transduced 
with RGD4C/AAVP-CMV-GFP (Figure 3A). Addition of 20 µM of 5-Aza increased the percentage of 
GFP positive cells to 17.5% compared to 3.5% of control untreated cells, and boosted the MFI by  
8.9-fold. In contrast, 5-Aza treatment of 9L cells transduced with the RGD4C/AAVP-Grp78-GFP 
phage resulted in no significant change in GFP expression (Figure 3B). Extensive methylation of the 
CMV promoter sequences has previously been reported [12,13,16,20]. Chromatin structural alterations 
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in the CMV promoter region were also described following suppression of expression of genes stably 
delivered by AAV vectors carrying the CMV promoter [21,22]. 
Figure 2. HDAC inhibitors restore gene expression from RGD4C/AAVP-CMV and boost 
RGD4C/AAVP-Grp78-mediated gene expression in cancer cells. U87 cells at day 75  
post-transduction with (A) RGD4C/AAVP-CMV-GFP or (B) RGD4C/AAVP-Grp78-GFP 
were plated in 6 well plates, then treated 24 h later with various concentrations of the 
HDAC inhibitors TSA, SAHA, nicotinamide or VPA for three days; (C) 9L cells stably 
transduced with RGD4C/AAVP-Grp78-GFP were treated with various concentrations of 
the HDAC inhibitors at day 97 post-transduction as described above. Finally, U87 and 9L 
cells were collected and GFP positive cells as well as the MFI were analyzed by flow 
cytometry. The experiments were performed in triplicate, repeated three times with similar 
results, and a representative experiment is shown. Error bars represent standard error of the 
mean (s.e.m). p-values were generated by ANOVA and denoted as follows: * p < 0.05,  
** p < 0.01 and *** p < 0.001. 
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Figure 2. Cont. 
 
Figure 3. Treatment with the DNA methylation inhibitor 5-Aza restores gene expression 
from RGD4C/AAVP-CMV in 9L glioblastoma cells. 9L cells stably transduced with (A) 
RGD4C/AAVP-CMV-GFP or (B) RGD4C/AAVP-Grp78-GFP were kept for 97 days in 
culture, then plated in 6 well plates and treated 24 h later with increasing concentrations of  
5-Aza. At day three, post 5-Aza treatment, cells were collected and GFP positive cells as 
well as the MFI were analyzed by flow cytometry. The experiments were repeated three 
times, in triplicate, with similar results and shown are data from a representative 
experiment. Statistical analyses were performed as described in Figures 1 and 2. 
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HDACs are upregulated in cancer. Therefore, HDAC inhibitors could be combined to restore 
RGD4C/AAVP-CMV efficacy or enhance RGD4C/AAVP-Grp78 in cancer cells specifically. Another 
interesting observation was a dose-dependent induction of the Grp78 promoter by TSA and SAHA in 
both 9L and U87 cells at the MFI level only, without any effect on the GFP positive cells. These data 
show that the GFP positive cells remain stable over time in RGD4C/AAVP-Grp78-GFP-transduced 
cells, confirming the absence of Grp78 promoter silencing and that treatment with HDAC inhibitors 
further enhance gene expression from RGD4C/AAVP-Grp78. Activation of the Grp78 promoter by 
TSA in various cancer cells has been reported [23]. Moreover, Grp78 induction by HDAC inhibitors 
was detected in xenograft models and biopsies from breast cancer patients undergoing TSA treatment [23]. 
HDAC inhibitors are considered potential candidates for cancer treatment [24]. For example, SAHA 
has recently been approved by the US Food and Drug Administration as a new class of anti-cancer 
drugs with potential against cutaneous T cell lymphoma [25]. SAHA has also been used in phase I and 
II clinical trials for hematological malignancies and solid tumors [26,27]. Nevertheless, HDAC 
inhibitors are considered poor drugs against solid tumors [26,28].  
Grp78 is a stress-inducible gene that supports cell survival and drug resistance [29] and cancer cell 
chemoresistance increases with stress mediated by cell confluence. Therefore, we investigated whether 
cell confluence induces Grp78 activity. Transduced U87 and 9L cells were grown until 70% 
confluence. Subsequently, GFP expression analysis by flow cytometry over time revealed that the 
percentage of GFP positive cells and MFI remained constant in both U87 and 9L cells transduced with 
either RGD4C/AAVP-CMV-GFP or RGD4C/AAVP-Grp78-GFP vectors (Figure 4). These data 
provide evidence that cell confluence does not affect the RGD4C/AAVP-Grp78 activity.  
Figure 4. Assessment of the effect of cell confluence on AAVP-driven gene expression in 
stably transduced cells. U87 and 9L populations of pooled clones stably transduced  
with RGD4C/AAVP-CMV-GFP or RGD4C/AAVP-Grp78-GFP, were plated at 300,000 
cells/well in 6 well plates and flow cytometry analysis was performed to quantify GFP 
expression over the indicated times. Shown are percentage of GFP positive cells and MFI 
derived from transduction with either the RGD4C/AAVP-CMV-GFP or RGD4C/AAVP-
Grp78-GFP. Day one represents 70% confluent cells while days 10 or 7 are the upper-limit 
time points at which overgrown cells could still be kept alive The experiments were 
repeated three times, in triplicate. n.s. = non-significant. 
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3. Experimental  
3.1. Cell Culture 
The human U87 glioblastoma cell line was obtained from the Cancer Research UK and the rat 9L 
glioblastoma cell line was kindly provided by Dr. Hrvoje Miletic, University of Bergen, Norway. 
These cell lines were maintained in Dulbecco’s Modified Eagle Medium supplemented with Fetal 
Bovine Serum (FBS), L-glutamine, penicillin, and streptomycin. 
3.2. Vector Construction and Phage Production 
To generate the double-targeted RGD4C/AAVP-Grp78-GFP and targeted RGD4C/AAVP-CMV-
GFP vectors carrying the puro
R
 resistance gene, a puromycin resistance cassette was cloned into the 
SacI site of AAVP vector located next to the AAV transgene cassette. First, the 1,168 bp fragment 
containing the puromycin resistance gene under the control of SV40 early enhancer/promoter was 
released from the pGL4.20 plasmid (promega) by BamHI and SalI double restriction digestion then 
ligated to SacI linkers and subsequently inserted into SacI site of the RGD4C/AAVP-Grp78-GFP and 
RGD4C/AAVP-CMV-GFP phage plasmids. Phage viral particles were amplified as described [7] then 
expressed as bacterial transducing units (TU/μL). 
3.3. Generation of Stably Transduced Cells 
The U87 or 9L cells, 70% confluent, were transduced with either double targeted RGD4C/AAVP-
Grp78-GFP or targeted RGD4C/AAVP-CMV-GFP phage encoding the GFP reporter gene and 
carrying the puro
R
, at 2 × 10
6
 TU/cell. At day three, post-vector transduction, cells were trypsinized 
and suspended in medium containing an appropriate dose of puromycin (1 µg/mL for U87 cells and  
7 µg/mL for 9L cells). Parental non-transduced cells were used as controls. The medium was removed 
and replaced with fresh medium containing puromycin every two to three days. After two weeks, all 
control cells were killed and puromycin-resistant single cell clones, which were derived from single 
cells, were monitored under the microscope. When the puromycin-resistant cell clones were visible, 
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they were pooled to produce a population of stably transduced cells. All stable selected cells were 
maintained in medium containing puromycin, imaged and monitored under a fluorescent microscope 
every two to three days, then further analyzed by FACS. 
3.4. Fluorescence Activated Cell Sorting (FACS) 
The percentage of cells expressing GFP following stable cell transduction with either 
RGD4C/AAVP-Grp78-GFP
 
or RGD4C/AAVP-CMV-GFP was determined by using FACS. U87 and 
9L cells were seeded in 6 well plates at a density of 3 × 10
5
 cells/well. After 48 h, cells were 
resuspended in PBS containing 0.5% FBS, then analyzed by using a FACScalibur instrument. A total 
of 20,000 individual cells were mounted within a manual gate in each condition.  
To validate reactivation of the CMV promoter activity, stably transduced U87 and 9L cells as well 
as parental control cells, were seeded in 6 well plates. After 24 h, cells were treated with DNA 
methyltransferase or HDACs inhibitor drugs, then monitored by fluorescent microscope. Afterwards, 
cells were washed, trypsinized and resuspended in PBS containing 0.5% FBS then analyzed by FACS. 
The mean fluorescence intensity (MFI), used to define the fluorescence intensity of each cell 
population, and the percentage of GFP positive cells were calculated by normalizing to the control 
(parental cells grown in similar condition). Data were analyzed using FlowJo software. 
3.5. Statistical Analyses 
Statistical analyses were performed by using GraphPad Prism software (version 5.0). Error bars 
represent standard error of the mean (s.e.m). p values were generated by ANOVA and denoted as 
follows: * p < 0.05, ** p < 0.01 and *** p < 0.001. 
4. Conclusions 
Our findings show that histone deacetylation and DNA methylation are involved, at least in part, in 
the long-term gene expression silencing from the parental RGD4C/AAVP bacteriophage gene delivery 
vector. Specifically, we have presented a novel strategy to advance gene transfer to cancer cells by 
bacteriophage by combining AAVP with inhibitors of histone deacetylation and DNA methylation. 
Additionally, our findings prove that combination of Grp78-guided gene expression and HDAC 
inhibitors provides novel and most suitable strategy to enhance cancer gene therapy by the AAVP 
phage-derived vector, and should be considered for clinical applications against solid tumors.  
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